טוען...
Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxicities
BACKGROUND: Phase I studies rely on investigators to accurately attribute of adverse events as related or unrelated to study drug. This information is ultimately used to help establish a safe dose. Patterns of physician attribution in the Phase I setting have not been widely studied and assessing th...
שמור ב:
| הוצא לאור ב: | Clin Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4819316/ https://ncbi.nlm.nih.gov/pubmed/26324741 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-0339 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|